Snapshot from Jul 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Erasca securities class action deadline
Regulatory securities class action

Erasca securities class action deadline

Analysis based on 12 articles · First reported Jun 30, 2026 · Last updated Jul 10, 2026

Sentiment
-30
Attention
2
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The lawsuit may negatively impact Erasca's stock price due to potential liability and reputational damage. The biotech sector may see increased scrutiny on drug candidate comparisons.

biotechnology pharmaceutical
Event Summary

Rosen Law Firm reminds Erasca investors of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the Class Period from January 14, 2025 to April 26, 2026. Specifically, Erasca touted ERAS-0015 as a potential 'best-in-class' therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. When the true details entered the market, investors suffered damages. The class action seeks compensation for purchasers of Erasca common stock during the Class Period.

Key Actions
93 Erasca made false statements
90 Rosen Law Firm announced class action lawsuit Erasca
75 The Schall Law Firm reminded investors of lawsuit Erasca
Entities Involved
stock
Erasca
Erasca is the defendant in the securities class action, facing allegations of false statements about its drug candidate ERAS-0015. The lawsuit could result in financial damages and harm to its reputation.
Importance 100.0 Sentiment -60.0
priv
Rosen Law Firm
Rosen Law Firm is the plaintiff's counsel, representing investors in the class action. The firm benefits from increased visibility and potential fees if the case succeeds.
Importance 50.0 Sentiment 10.0
stock
Revolution Medicines
Revolution Medicines is mentioned as the competitor whose drug candidate RMC-6236 was used for comparison. The lawsuit may indirectly benefit Revolution Medicines if Erasca's claims are discredited.
Importance 30.0 Sentiment 20.0
per
Lawrence Rosen
Lawrence Rosen is a partner at Rosen Law Firm, involved in the class action. His role is primarily as legal counsel.
Importance 20.0 Sentiment 5.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm, providing contact for investors. His role is supportive to the litigation.
Importance 10.0 Sentiment 5.0
Relationships
Erasca competitor ↔ Revolution Medicines Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molec
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Lawrence Rosen founding partner ↔ Philip Kim Lawrence Rosen is a founding partner of the Rosen Law Firm, where he directs attorneys including Philip Kim. Together, t
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.